Genelux (GNLX) Shares Outstanding (Weighted Average) (2022 - 2026)
Genelux (GNLX) recorded quarterly Shares Outstanding (Weighted Average) of $44.2 million in Q1 2026, up 18.76% quarter-over-quarter from $37.2 million in Q4 2025, and up 26.41% on a YoY basis from $34.9 million in Q1 2025.
Genelux (GNLX) Shares Outstanding (Weighted Average) (2022 - 2026) Analysis & Trends
Genelux's Shares Outstanding (Weighted Average) history runs 5 years deep, the most recent figure standing at $44.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Weighted Average) rose 26.41% year-over-year to $44.2 million; the TTM figure through Mar 2026 stood at $44.2 million (up 26.41% YoY), while the FY2025 annual figure was $37.2 million, up 18.21% from the prior year.
- Shares Outstanding (Weighted Average) was $44.2 million for Q1 2026 at Genelux, up from $37.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $44.2 million in Q1 2026 to a low of $3120.0 in Q3 2023.
- Historically, Shares Outstanding (Weighted Average) has averaged $25.8 million across 5 years, with a median of $29.4 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) tumbled 99.97% in 2023, then surged 974438.94% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $9.1 million in 2022, then soared by 244.99% to $31.5 million in 2023, then changed by 0.0% to $31.5 million in 2024, then climbed by 18.21% to $37.2 million in 2025, then rose by 18.76% to $44.2 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $44.2 million (Q1 2026), $37.2 million (Q4 2025), and $37.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 44.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.15 Mn |
| Dec 31, 2025 | 37.18 Mn |
| Sep 30, 2025 | 37.89 Mn |
| Jun 30, 2025 | 37.95 Mn |
| Mar 31, 2025 | 34.93 Mn |
| Dec 31, 2024 | 31.45 Mn |
| Sep 30, 2024 | 30.41 Mn |
| Jun 30, 2024 | 28.31 Mn |
| Mar 31, 2024 | 26.85 Mn |
| Dec 31, 2023 | 31.45 Mn |
| Sep 30, 2023 | 3,120.00 |
| Jun 30, 2023 | 25.07 Mn |
| Mar 31, 2023 | 19.58 Mn |
| Dec 31, 2022 | 9.12 Mn |
| Sep 30, 2022 | 9.12 Mn |
| Mar 31, 2022 | 9.11 Mn |